These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32341095)

  • 21. Doc2 Proteins Are Not Required for the Increased Spontaneous Release Rate in Synaptotagmin-1-Deficient Neurons.
    Díez-Arazola R; Meijer M; Bourgeois-Jaarsma Q; Cornelisse LN; Verhage M; Groffen AJ
    J Neurosci; 2020 Mar; 40(13):2606-2617. PubMed ID: 32098902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transmembrane tethering of synaptotagmin to synaptic vesicles controls multiple modes of neurotransmitter release.
    Lee J; Littleton JT
    Proc Natl Acad Sci U S A; 2015 Mar; 112(12):3793-8. PubMed ID: 25775572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A de novo missense mutation in synaptotagmin-1 associated with neurodevelopmental disorder desynchronizes neurotransmitter release.
    van Boven MA; Mestroni M; Zwijnenburg PJG; Verhage M; Cornelisse LN
    Mol Psychiatry; 2024 Jun; 29(6):1798-1809. PubMed ID: 38321119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alcohol induces synaptotagmin 1 expression in neurons via activation of heat shock factor 1.
    Varodayan FP; Pignataro L; Harrison NL
    Neuroscience; 2011 Oct; 193():63-71. PubMed ID: 21816209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model.
    Douaud M; Feve K; Pituello F; Gourichon D; Boitard S; Leguern E; Coquerelle G; Vieaud A; Batini C; Naquet R; Vignal A; Tixier-Boichard M; Pitel F
    PLoS One; 2011; 6(10):e26932. PubMed ID: 22046416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
    J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.
    Löscher W; Gillard M; Sands ZA; Kaminski RM; Klitgaard H
    CNS Drugs; 2016 Nov; 30(11):1055-1077. PubMed ID: 27752944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of stoned and synaptotagmin in synaptic vesicle endocytosis.
    Fergestad T; Broadie K
    J Neurosci; 2001 Feb; 21(4):1218-27. PubMed ID: 11160392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy.
    Menten-Dedoyart C; Serrano Navacerrada ME; Bartholome O; Sánchez Gil J; Neirinckx V; Wislet S; Becker G; Plenevaux A; Van den Ackerveken P; Rogister B
    PLoS One; 2016; 11(11):e0166525. PubMed ID: 27861538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.
    Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y
    Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low distribution of synaptic vesicle protein 2A and synaptotagimin-1 in the cerebral cortex and hippocampus of spontaneously epileptic rats exhibiting both tonic convulsion and absence seizure.
    Hanaya R; Hosoyama H; Sugata S; Tokudome M; Hirano H; Tokimura H; Kurisu K; Serikawa T; Sasa M; Arita K
    Neuroscience; 2012 Sep; 221():12-20. PubMed ID: 22766234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype.
    Rassu M; Biosa A; Galioto M; Fais M; Sini P; Greggio E; Piccoli G; Crosio C; Iaccarino C
    J Cell Mol Med; 2019 Dec; 23(12):8505-8510. PubMed ID: 31560168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential expression of synaptic vesicle protein 2A after status epilepticus and during epilepsy in a lithium-pilocarpine model.
    Contreras-García IJ; Pichardo-Macías LA; Santana-Gómez CE; Sánchez-Huerta K; Ramírez-Hernández R; Gómez-González B; Rocha L; Mendoza Torreblanca JG
    Epilepsy Behav; 2018 Nov; 88():283-294. PubMed ID: 30336420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphatidylserine is critical for vesicle fission during clathrin-mediated endocytosis.
    Varga K; Jiang ZJ; Gong LW
    J Neurochem; 2020 Jan; 152(1):48-60. PubMed ID: 31587282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.
    Nowack A; Malarkey EB; Yao J; Bleckert A; Hill J; Bajjalieh SM
    PLoS One; 2011; 6(12):e29560. PubMed ID: 22220214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-128 regulates epilepsy sensitivity in mice by suppressing SNAP-25 and SYT1 expression in the hippocampus.
    Wang P; Zhang Y; Wang Z; Yang A; Li Y; Zhang Q
    Biochem Biophys Res Commun; 2021 Mar; 545():195-202. PubMed ID: 33571908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broadening the phenotypic spectrum of the presumably epilepsy-related SV2A gene variants.
    Badura-Stronka M; Kuszel Ł; Wencel-Warot A; Cudnoch K; Wołyńska K; Rutkowska K; Steinborn B; Płoski R
    Epilepsy Res; 2023 Feb; 190():107101. PubMed ID: 36758444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coordinated bi-directional trafficking of synaptic vesicle and active zone proteins in peripheral nerves.
    Juranek JK; Mukherjee K; Jahn R; Li JY
    Biochem Biophys Res Commun; 2021 Jun; 559():92-98. PubMed ID: 33933994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy].
    Tokudome K; Shimizu S; Serikawa T; Ohno Y
    Nihon Yakurigaku Zasshi; 2018; 152(6):275-280. PubMed ID: 30531097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.